New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small ...

This news is for Australian Media only Eflornithine is now reimbursed by the government under Australia's Pharmaceutical ...

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

NovoCure faces margin pressure, slow launches, and adoption hurdles beyond GBM, despite revenue beats and pipeline hopes.

In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in ...

Panelists discuss how the unprecedented 5-year progression-free survival benefit (60% vs 8%) demonstrated in the CROWN trial ...